title: A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.
abstract: New detection methods with prognostic power are needed for early identification of dysplasia and esophageal adenocarcinoma (EA) in patients with Barrett's esophagus (BE). This study assessed the relative sensitivity and specificity of conventional cytology, DNA ploidy analysis with digital image analysis (DIA), and fluorescence in situ hybridization (FISH) for the detection of dysplasia and adenocarcinoma in endoscopic brushing specimens from 92 patients undergoing endoscopic surveillance for BE. FISH used probes to 8q24 (C-MYC), 9p21 (P16), 17q12 (HER2), and 20q13. Four-quadrant biopsies taken every centimeter throughout visible Barrett's mucosa were used as the gold standard. The sensitivity of cytology, DIA, and FISH for low-grade dysplasia was 5%, 5%, and 50%, respectively; for high-grade dysplasia (HGD), 32%, 45%, and 82%, respectively; and for EA, 45%, 45%, and 100%, respectively. FISH was more sensitive (P < .05) than cytology and DIA for low-grade dysplasia, HGD, and EA. The specificity of cytology, DIA, and FISH among patients (n = 14) with tissue showing only benign squamous mucosa was 93%, 86%, and 100% (P = .22), respectively. All patients with a polysomic FISH result had HGD and/or EA within 6 months (n = 33). There was a significant difference between FISH categories (negative, 9p21 loss, gain of a single locus, and polysomy) for progression to HGD/EA (P < .001). These findings suggest that FISH has high sensitivity for the detection of dysplasia and EA in BE patients, with the power to stratify patients by FISH abnormality for progression to HGD/EA. Additional studies are needed to further evaluate the clinical use of FISH.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
authors.forename: Emily G Barr
authors.initials: EG
authors.lastname: Fritcher
authors.forename: Shannon M
authors.initials: SM
authors.lastname: Brankley
authors.forename: Benjamin R
authors.initials: BR
authors.lastname: Kipp
authors.forename: Jesse S
authors.initials: JS
authors.lastname: Voss
authors.forename: Michael B
authors.initials: MB
authors.lastname: Campion
authors.forename: Larry E
authors.initials: LE
authors.lastname: Morrison
authors.forename: Mona S
authors.initials: MS
authors.lastname: Legator
authors.forename: Lori S
authors.initials: LS
authors.lastname: Lutzke
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Wang
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Sebo
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Halling
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000209:etiology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000150:complications*; D001707:Biopsy, Needle; D003581:Cytodiagnosis; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000209:etiology; D004945:Esophagoscopy; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D011003:Ploidies; D011230:Precancerous Conditions / Q000175:diagnosis* / Q000209:etiology; D012680:Sensitivity and Specificity
chemical_list: D004273:DNA, Neoplasm